Alkermes Business Summary

Alkermes plc (ALKS) is a fully integrated global biopharmaceutical company that generates revenue through a dual-stream model comprising the net sales of its proprietary product portfolio and recurring manufacturing and royalty fees from third-party licenses. The company’s primary business segments are focused on neuroscience, specifically psychiatry and addiction, with a commercial lineup featuring Lybalvi (schizophrenia and bipolar I disorder), Aristada (long-acting injectable for schizophrenia), and Vivitrol (opioid and alcohol dependence). In early 2026, Alkermes significantly expanded its therapeutic footprint into the sleep medicine market through the $2.37 billion acquisition of Avadel Pharmaceuticals, integrating the once-nightly narcolepsy treatment LUMRYZ into its commercial operations. Direct competitors include Indivior PLC, Jazz Pharmaceuticals, and Braeburn Pharmaceuticals; Alkermes maintains a distinct competitive advantage as a specialized leader in long-acting injectable (LAI) technologies and complex drug delivery systems for chronic central nervous system (CNS) conditions. Originally founded in 1987 by Michael Wall and the late Dr. Floyd Bloom, the company is currently led by Richard Pops, who has served as Chairman and CEO since 1991 and is credited with transitioning the firm from a private technology provider to a public commercial powerhouse. The executive leadership team includes Joshua Reed, who was appointed Chief Financial Officer in September 2025, and Blair C. Jackson, the Executive Vice President and Chief Operating Officer. The company’s strategic direction is supported by a board of directors featuring industry veterans such as Dr. Richard Gaynor and Frank "Andy" Wilson. Notable institutional influence is exerted by activist investor Sarissa Capital Management, which has historically pushed for value-unlocking initiatives, alongside major shareholders like The Vanguard Group and T. Rowe Price.